Disclosures for "VAMP-1 associated congenital myasthenic syndrome: a demonstrative case with response to low-dose pyridostigmine")
-
Dr. Drakou has nothing to disclose.
-
Dr. Delfiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Delfiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Gene Therapies. Dr. Delfiner has received personal compensation in the range of $500-$4,999 for serving as a MDA Engage Event Chair and speaker with Muscular Dystrophy Association.